CGON Stock Summary and Trading Ideas (CG Oncology | NASDAQ:CGON)

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

CG Oncology trades on the NASDAQ stock market under the symbol CGON.

As of August 12, 2026, CGON stock price declined to $76.99 with 634,797 million shares trading.

CGON has a beta of 0.69, meaning it tends to be less sensitive to market movements. CGON has a correlation of 0.03 to the broad based SPY ETF.

CGON has a market cap of $6.82 billion. This is considered a Mid Cap stock.

Last quarter CG Oncology reported $1 million in Revenue and -$.90 earnings per share. This beat revenue expectation by $325,208 and missed earnings estimates by -$.25.

The top ETF exchange traded funds that CGON belongs to (by Net Assets): VTI, IWM, XBI, VB, VXF.

CGON has outperformed the market in the last year with a price return of +221.5% while the SPY ETF gained +22.7%. CGON has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +11.1% and +6.0%, respectively, while the SPY returned +4.7% and +4.3%, respectively.

CGON support price is $74.37 and resistance is $79.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGON shares will trade within this expected range on the day.